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investigating the effects of female sex hormones on the airways. http://bit.ly/2JAZuXh
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ABSTRACT In observational studies, early menopause is associated with lower forced vital capacity
(FVC) and a higher risk of spirometric restriction, but not airflow obstruction. It is, however, unclear if
this association is causal. We therefore used a Mendelian randomisation (MR) approach, which is not
affected by classical confounding, to assess the effect of age at natural menopause on lung function.
We included 94742 naturally post-menopausal women from the UK Biobank and performed MR
analyses on the effect of age at menopause on forced expiratory volume in 1 s (FEV1), FVC, FEV1/FVC,
spirometric restriction (FVC<lower limit of normal (LLN)) and airflow obstruction (FEV1/FVC<LLN). We
used the inverse variance-weighted method, as well as methods that adjust for pleiotropy, and compared
MR with observational analyses.
The MR analyses showed higher FEV1/FVC and a 15% lower risk of airflow obstruction for women with
early (<45 years) compared to normal (45–55 years) menopause. Despite some evidence of pleiotropy, the
results were consistent when using MR methods robust to pleiotropy. Similar results were found among
never- and ever-smokers, while the protective effect seemed less strong in women who had ever used
menopause hormone treatment and in overweight women. There was no strong evidence of an association
with FVC or spirometric restriction. In observational analyses of the same dataset, early menopause was
associated with a pronounced reduction in FVC and a 13% higher risk of spirometric restriction.
Our MR results suggest that early menopause has a protective effect on airflow obstruction. Further
studies are warranted to better understand the inconsistency with observational findings, and to investigate
the underlying mechanisms and role of female sex hormones.
This article has supplementary material available from erj.ersjournals.com
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Introduction
Women are more susceptible to chronic obstructive pulmonary disease (COPD) than men, especially
never-smokers [1], and it is speculated that these sex differences arise partly from distinct sex hormone
patterns during life [2]. A major shift in sex hormone levels occurs during menopause. Age at natural
menopause shows considerable variability among women, normally occurring between 45 and 55 years of
age, with an average of 51 years in European women [3]. As populations age, the proportion of the female
population living in a post-menopausal state is increasing and we need to better understand the impact of
this major biological event on respiratory health and health in general.
A recent systematic review supports an association of menopause with lower forced expiratory volume in
1 s (FEV1) and lower forced vital capacity (FVC) [4]. A large study in the UK Biobank (UKB) showed that
women with an earlier age at menopause had lower FEV1 and FVC, and a higher risk of spirometric
restriction, while no association was found with airflow obstruction [5]. These observational studies may
suffer from residual confounding even when the analyses are adjusted for known confounders, including
anthropometric, lifestyle, socio-economic and reproductive characteristics. Potential confounders may also
include early life events, diet and physical activity, and there could be other, yet unrecognised, factors
associated with both age at menopause and lung function [6, 7].
The Mendelian randomisation (MR) approach can help to assess the causal effect of age at menopause on
lung function [8]. With MR, genetic variants, i.e. single nucleotide polymorphisms (SNPs), are used as
proxies (“instrumental variables”) for age at menopause [9]. The alleles of a genetic variant are randomly
allocated at conception and therefore not affected by classical confounding. Finding that the SNPs
predisposing to earlier age at menopause are associated with lung function would provide indirect
evidence of a causal effect, as long as the assumptions underlying MR hold (figure 1) [8]. Of particular
concern is pleiotropy, which is present when an SNP is also associated with other traits affecting lung
function, independently from age at menopause [8, 10].
In the current study, we used MR to estimate the effect of age at menopause on five lung function
outcomes (FVC, FEV1, FEV1/FVC, spirometric restriction and airflow obstruction) using data from the
UKB. We categorised menopause as early, normal and late to allow for the investigation of possible
nonlinear effects. Early menopause is of particular clinical interest and has been most commonly
investigated for associations with health outcomes in previous studies. We assessed the robustness of our
main MR results using methods to investigate and adjust for pleiotropy, and we performed subgroup
analyses to investigate whether the effect of age at menopause on lung function varied according to
smoking status, use of menopause hormone therapy (MHT) and body mass index (BMI). We also
performed classical observational analyses on the same dataset, for comparison with MR.
Methods
Detailed methods are provided in the supplementary data.
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FIGURE 1 Schematic overview of Mendelian randomisation (MR). For each single nucleotide polymorphism
(SNP), the MR effect estimate is calculated using the GX (association of the SNP with early and late
menopause versus normal menopause) and GY (association of the SNP with lung function
outcomes) associations. MR assumptions: 1) relevance assumption: SNPs are associated with exposure (age
at menopause); 2) independent assumption: the association between SNP and outcome is NOT confounded;
and 3) exclusion restriction assumption: SNPs affect outcome (lung function) only through the exposure and
not through independent pathways (i.e. absence of pleiotropy). BMI: body mass index.
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Study population
We included naturally post-menopausal white women from the very large, population-based UKB study [11],
and excluded women with surgical menopause and women with extreme age at menopause (<40 years or
>60 years). Age at natural menopause was based on self-reported age at which “periods stopped”, and was
categorised as early (40–45 years), normal (45–55 years), or late (55–60 years), using normal as the
reference category. We investigated the continuous outcomes FEV1, FVC and FEV1/FVC (best measure),
as well as the binary outcomes of spirometric restriction defined as FVC<lower limit of normal (LLN) and
airflow obstruction defined as FEV1/FVC<LLN. The LLN was based on the Global Lung Function
Initiative 2012 equations [12].
SNP selection
Based on published genome-wide association studies, we identified 80 SNPs associated with continuous
age at menopause at a p-value threshold of 5×10−8 [13–18]. After removing SNPs with F-statistic ⩽10 to
avoid weak instrument bias and SNPs highly correlated with each other (r2⩾0.8), 63 SNPs remained that
jointly explained 6% of the UKB population variance of age at menopause [19]. Of the selected SNPs, 39
SNPs were strong instruments for early menopause and 40 for late menopause.
MR analyses
As our main analysis, we estimated the causal effect of early and late menopause on lung function. As
secondary analyses, we performed MR analyses considering age at menopause as a continuous variable.
For each of the included SNPs we obtained two estimates from UKB (figure 1): one for the association of
the SNP with early and late menopause versus normal menopause (GX), using logistic regression adjusted
for centre, first 10 ancestry principal components and three genotyping batches; and one for the
association with the lung function outcomes (GY), using logistic (airway obstruction and spirometric
restriction) or linear (FEV1/FVC, FVC and FEV1) regression adjusted for age, age2, height, centre,
10 principal components and three batches. For each SNP, an MR estimate was derived as the ratio of GY
over GX (Wald estimator) and its standard error obtained using the Delta method [20]. SNP-specific MR
estimates were then pooled using an inverse variance-weighted (IVW) fixed-effect meta-analysis method
that accounts for correlation between SNPs (R package MendelianRandomization; R Foundation for
Statistical Computing, Vienna, Austria) [19, 21]. We used the IVW two-sample MR method because the
standard MR approach in a one-sample setting (as in our study), which is the two-stage least squares
(2SLS) method, does not account for pleiotropy.
Assessing pleiotropy
The presence of pleiotropy was investigated using between-instrument heterogeneity of the IVW MR
estimates, based on the I2 statistic and Q test [22]. In secondary analyses we investigated the robustness of
our findings to pleiotropy using MR methods based on different assumptions about the direction of
possible pleiotropic effects: 1) IVW random-effect meta-analysis (assumes random pleiotropic effects);
2) weighted median analysis (assumes that at least 50% of the SNPs are valid inverse variances with no
assumption on the direction of pleiotropic effects); 3) MR-Egger regression with penalised weights
(assumes directional pleiotropic effects); and 4) MR-PRESSO (corrects for horizontal pleiotropy by
removing pleiotropic outlier SNPs) [10, 23–25]. Furthermore, we a priori considered height, BMI and age
at menarche as potential sources of pleiotropy. We excluded SNPs that were associated with these traits at a
p-value <7.9×10−4 (Bonferroni correction, 0.05/63) based on information from the online PhenoScanner [26].
Sensitivity analyses
We performed several sensitivity analyses to assess the robustness of our findings to choices made a priori
for our MR analyses. These related to the MR method used, the sample used and the choice of SNPs used
as instruments: 1) we performed the standard MR analysis for the one-sample setting, i.e. the 2SLS
regression analysis, which assumes no pleiotropy similarly to the IVW fixed-effect method [27]; 2) we
restricted the main MR analysis to exactly the same number of women included in the observational
analysis to allow comparison between the two approaches (n=84844); 3) we excluded asthmatic women
because these women may have reversible airflow obstruction; and 4) we limited the MR analyses to the 54
SNPs identified by the most recent and largest genome-wide association study on age at menopause [18]
and did not adjust for correlation (the 54 SNPs are independent) or remove weak SNPs in these analyses.
Finally, we used GX estimates for continuous age at menopause from DAY et al. [18], together with the GY
estimates from UKB, to further investigate the robustness of our findings when using two independent
data sources (two-sample MR) instead of a single dataset (one-sample MR).
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Subgroup analyses
For the lung function outcomes with consistently significant findings, we performed subgroup analyses by
smoking status (never versus ever) because some evidence suggests that a longer exposure to female sex
hormones might increase airway susceptibility to the effects of smoking [28, 29]. In addition, we
investigated potential effect modification by MHT use (never versus ever) and BMI (low versus high based
on a cut-off of 26 kg·m−2 (median)), because women taking hormonal therapy and obese women may still
have high levels of female sex hormones after menopause.
Observational analyses
Earlier observational analyses in UKB examined age at menopause as a categorical variable divided into
five groups [5]. For comparison with our MR findings, we performed observational analyses in UKB using
three menopause categories. Moreover, in addition to confounders previously considered (centre, age, age2,
height, BMI, smoking groups, Townsend deprivation index, MHT use, number of live births, ever use of
oral contraceptives and age at menarche), we also included physical activity and education level [6, 7, 30].
All analyses were performed using R (R Foundation for Statistical Computing).
Results
Population characteristics
From the UKB, 94742 white women who had undergone natural menopausal were included in the MR
analyses, of which 7206 had early and 8468 had late menopause (table 1 and supplementary table S1). The
mean age was 60 years and mean age at menopause 51 years; 57% of women had never used MHT, 7%
had spirometric restriction (FVC<LLN) and 8% had airflow obstruction (FEV1/FVC<LLN). Women with
late menopause were less likely to have ever smoked or to have ever used MHT compared to women with
early menopause. Only 84844 of these women had complete data on all confounders and were included in
the observational analyses, and their characteristics were the same as those of the MR sample (table 1 and
supplementary table S1).
TABLE 1 Characteristics of the study population
Women included
in MR
Women with
complete data#
Women with early
menopause
Women with late
menopause
Subjects n 94742 84844 7206 8468
Age years 60±5.3 60±5.3 59±6.8 62±3.4
Height cm 162±6.1 162±6.1 162±6.2 162±6.0
BMI kg·m−2 26.9±4.9 26.8±4.8 27.0±5.0 27.5±5.0
Age at menopause years 51±4.0 51±4.0 42±1.4 57±1.2
Early menopause (<45 years) 7206 (7.6) 6369 (7.5) 7206 (100)
Late menopause (>55 years) 8468 (8.9) 7541 (8.9) 8468 (100)
Age at menarche years 13±1.6 13±1.6 13±2.9 13±2.4
Lung function
FVC % pred 97.4±15.7 97.7±15.6 95.7±15.9 97.5±15.6
FEV1 % pred 93.1±16.8 93.4±16.7 91.1±17.3 93.3±16.8
FEV1/FVC 75.3±6.3 75.3±6.3 75.1±6.7 75.2±6.3
FEV1/FVC<LLN 7979 (8.4) 7010 (8.3) 727 (10) 637 (7.5)
FVC<LLN 6869 (7.3) 5892 (6.9) 650 (9.0) 585 (6.9)
Asthma¶ 10900 (12) 9726 (11) 926 (13) 993 (12)
Smoking status
Never-smoker 53831 (57) 48393 (57) 3633 (50) 4995 (59)
Ex-smoker 33518 (35) 30194 (36) 2685 (37) 3016 (36)
Current-smoker 7370 (8) 6257 (7) 884 (12) 455 (5)
Pack-years in smokers 21±16 20±15 24±16 20±16
MHT
Never used 53946 (57) 48395 (57) 3201 (45) 4390 (52)
Ex-user 36261 (38) 32407 (38) 3459 (48) 3739 (44)
Current user 4375 (5) 4042 (5) 532 (7) 328 (4)
Data are reported as mean±SD or n (%), unless otherwise stated. See supplementary table S1 for more
variables and subgroups. MR: Mendelian randomisation; BMI: body mass index; FVC: forced vital capacity;
FEV1: forced expiratory volume in 1 s; LLN: lower limit of normal; MHT: menopause hormone therapy.
#: women with complete data on all variables included in the observational analyses; ¶: self-reported
doctor-diagnosed asthma ever.
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Detailed results of all MR and observational analyses, separately for early and late menopause, can be
found in supplementary table S2 (GX and GY effect estimates) and supplementary table S3 (MR results).
MR analyses
For early menopause (table 2), the MR analyses showed higher FEV1 (5.55 mL, 95% CI 0.92–10.18 mL),
higher FEV1/FVC (0.29%, 95% CI 0.22%–0.36%) and a 15% lower risk of airflow obstruction (OR 0.85,
95% CI 0.82–0.89), as compared to normal menopause (figure 2 and supplementary table S3). No effect of
early menopause was found for FVC (−4.98 mL, 95% CI −10.5–0.53 mL) or spirometric restriction (OR
1.03, 95% CI 0.99–1.08).
For late menopause (table 3), the MR analyses showed lower FEV1 (−11.0 mL, 95% CI −16.4–−5.68 mL)
and lower FEV1/FVC (−0.18%, 95% CI −0.26%–−0.10%), and moderately higher risk of airflow
obstruction (OR 1.06, 95% CI 1.01–1.11) (figure 2 and supplementary table S3). Late menopause was also
borderline significantly associated with lower FVC (−7.10 mL, 95% CI −13.5–−0.75 mL) but not with
spirometric restriction (OR 1.00, 95% CI 0.95–1.05).
These results were consistent when considering age at menopause as a continuous variable, with an
increase in age at menopause associated with lower FEV1, lower FEV1/FVC and a higher risk of
obstruction (supplementary table S4).
Assessing pleiotropy
Heterogeneity was low for the analyses on spirometric restriction and airflow obstruction (I2=0%–20%;
Q p=0.098–3.2×10−4; global test p=0.05–0.22). For the continuous lung function outcomes, the high I2
(46%–53%), the significant Q test (p=1.0×10−5–5.2×10−10) and significant global test of MR-PRESSO
(p<0.0005) suggested the presence of (horizontal) pleiotropy (supplementary table S3). Correcting for
horizontal pleiotropy by MR-PRESSO increased the effect estimate sizes but these were not significantly
different from the original MR estimates (distortion test p=0.43–0.94).
Overall, the results from the other MR methods robust to pleiotropy were consistent with those from the
main analysis (figure 2 and supplementary table S3). For FEV1/FVC and airflow obstruction, a protective
effect of early menopause was found for all MR methods. For FVC and spirometric restriction, the MR
estimates remained nonsignificant, except for the MR-Egger estimate of early menopause on spirometric
restriction (OR 1.12, 95% CI 1.00–1.24).
We further assessed the impact of pleiotropy by removing SNPs with potential pleiotropic effects. Out of 63
SNPs, 16 SNPs have previously been associated with height, five with (adult) BMI and four with age at menarche.
Removing these SNPs gave similar results for both FEV1/FVC and airflow obstruction compared to the main
analyses, indicating robustness to pleiotropy (tables 2 and 3 and supplementary table S3). However, we found a
TABLE 2 Association of early menopause with airflow obstruction in observational and Mendelian randomisation (MR) analyses
Subjects n SNPs n FEV1/FVC % FEV1/FVC<LLN
β (95% CI) p-value I2 (95% CI) OR (95% CI) p-value I2 (95% CI)
Observational analysis 77303 −0.19
(−0.34–−0.03)
0.019 NA 1.09 (1.00–1.19) 0.063 NA
Main MR analysis (all SNPs) 86274 39 0.29 (0.22–0.36) 1.48×10−16 48 (34–83) 0.85 (0.82–0.89) 5.88×10−14 16 (0–60)
Pleiotropic SNPs excluded
Height 86274 30 0.28 (0.21–0.36) 2.29×10−13 56 (47–88) 0.84 (0.81–0.88) 1.44×10−13 26 (0–70)
BMI 86274 36 0.29 (0.22–0.36) 1.93×10−16 55 (39–85) 0.85 (0.82–0.89) 7.60×10−14 19 (0–64)
Age at menarche 86274 36 0.29 (0.22–0.36) 1.02×10−14 49 (34–84) 0.84 (0.81–0.88) 2.85×10−14 19 (0–63)
All# 86274 28 0.29 (0.22–0.37) 7.13×10−14 57 (49–89) 0.84 (0.80–0.88) 1.19×10−13 30 (0–74)
Sensitivity MR analyses
Women with complete data¶ 77303 39 0.28 (0.21–0.35) 1.86×10−14 45 (25–80) 0.87 (0.84–0.91) 7.14×10−10 14 (0–58)
Non-asthmatic women 76367 39 0.31 (0.24–0.38) 7.47×10−18 42 (19–80) 0.84 (0.80–0.88) 2.07×10−12 7 (0–48)
Limiting to DAY et al. [18]
SNPs
86274 33 0.29 (0.18–0.39) 3.75×10−8 38 (5–77) 0.89 (0.84–0.95) 2.20×10−4 4 (0–54)
Significant results are shown in bold. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; LLN: lower limit of normal; SNP: single
nucleotide polymorphism; I2: between-instrument heterogeneity indicator; BMI: body mass index; NA: not applicable. #: all pleiotropic SNPs
associated with height, BMI and age at menarche excluded from the analysis and SNPs associated with the traits were selected based on the
results from the PhenoScanner with p<7.94×10−4 (0.05/63); ¶: women with complete data on all variables included in the observational
analyses.
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small detrimental effect of early menopause on FVC when excluding possible pleiotropic SNPs (−6.77 mL,
95% CI −12.8–−0.067 mL), but still no effect on spirometric restriction (OR 1.03, 95% CI 0.98–1.08).
Sensitivity analyses
Results consistent with the main analyses were found in all sensitivity analyses assessing the robustness of
our findings to choices made a priori (tables 2 and 3 for FEV1/FVC and airflow obstruction;
supplementary table S3 for all outcomes). These related to the MR method used (one-sample 2SLS (figure
2)), the sample used (same number as observational analyses and limited to non-asthmatic women), and
the choice of SNPs used as instruments (limiting to SNPs identified by DAY et al. [18]). We also found
consistent results when using GX estimates for continuous age at menopause from the literature [18] and
GY estimates from UKB (supplementary table S4).
Subgroup analyses
We hypothesised a possible stronger effect in smokers, but found no statistically significant difference in
MR estimates for FEV1/FVC and airflow obstruction between ever- and never-smokers (figure 3 and
supplementary table S5). In addition, we hypothesised that the protective effect of early menopause might
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FIGURE 2 Association of early and late menopause with airflow obstruction in observational and Mendelian
randomisation (MR) analyses. a, c) Early menopause: forced expiratory volume in 1 s (FEV1)/forced vital
capacity (FVC) (a) and airflow obstruction as measured by FEV1/FVC<lower limit of normal (LLN) (c). b, d) Late
menopause: FEV1/FVC (b) and FEV1/FVC<LLN (d). The observational analyses (linear/logistic regression) were
adjusted for age, age2, height, centre, body mass index, smoking groups, Townsend deprivation index, level of
education, physical activity, number of live births, age at menarche, ever oral contraceptive use and use of
menopause hormone therapy. All MR analyses were adjusted for age, age2, height, centre, first 10 principal
components and genotyping batch. Data are presented with 95% CI. For MR-PRESSO, both unadjusted
analyses (raw) and analyses after removal of outliers if any were detected (corrected) are shown. IVW: inverse
variance-weighted average method; 2SLS: two-stage least squares regression.
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be less evident in women who still had high levels of female sex hormones after menopause (i.e. MHT
users and overweight/obese women), and our findings support this hypothesis (figure 3 and
supplementary table S5). We found a significant difference in effect between never- and ever-MHT users;
the interaction was significant for airflow obstruction for both early and late menopause (p=0.002 and
0.004), while for FEV1/FVC the interaction was significant for early menopause (p=0.04) and borderline
for late menopause (p=0.07). In the subgroup analyses based on median BMI, the interaction was
significant for FEV1/FVC for both early and late menopause (p=4.6×10−7 and 0.005). For airflow
obstruction, the interaction was significant for early menopause (p=0.026) and borderline for late
menopause (p=0.07).
Observational analyses
In the observational analyses, women who experienced early menopause showed statistically significantly
lower FEV1 (−31.4 mL, 95% CI−42.0–−20.9 mL), lower FVC (−36.3 mL, 95% CI −48.8–−23.8 mL) and a
higher risk of spirometric restriction (OR 1.13, 95% CI 1.02–1.24) (figure 2 and supplementary table S3).
Early menopause was also associated with lower FEV1/FVC, although the confidence interval was very
large (−0.19%, 95% CI −0.34%–−0.03%), and possibly a higher risk of airflow obstruction (OR 1.09, 95%
TABLE 3 Association of late menopause with airflow obstruction in observational and Mendelian randomisation (MR) analyses
Subjects n SNPs n FEV1/FVC % FEV1/FVC<LLN
β (95% CI) p-value I2 (95% CI) OR (95% CI) p-value I2 (95% CI)
Observational analysis 78475 0.11 (−0.04–0.25) 0.139 NA 0.92 (0.84–1.02) 0.101 NA
Main MR analysis (all SNPs) 87536 40 −0.18 (−0.26–−0.10) 1.09×10−5 53 (44–84) 1.06 (1.01–1.11) 0.018 20 (0–58)
Pleiotropic SNPs excluded
Height 87536 31 −0.22 (−0.33–−0.11) 6.90×10−5 61 (49–86) 1.10 (1.03–1.17) 4.53×10−3 23 (0–60)
BMI 87536 37 −0.17 (−0.26–−0.09) 3.13×10−5 54 (44–85) 1.06 (1.01–1.11) 0.027 20 (0–59)
Age at menarche 87536 37 −0.23 (−0.33–−0.13) 7.32×10−6 56 (43–83) 1.11 (1.04–1.17) 1.09×10−3 24 (0–57)
All# 87536 28 −0.22 (−0.33–−0.11) 1.33×10−4 61 (49–87) 1.09 (1.02–1.17) 0.015 23 (0–61)
Sensitivity MR analyses
Women with complete data¶ 78475 40 −0.17 (−0.25–−0.08) 9.63×10−5 53 (44–84) 1.05 (1.00–1.11) 0.042 13 (0–51)
Non-asthmatic women 77562 40 −0.18 (−0.26–−0.10) 1.79×10−5 53 (44–83) 1.06 (1.00–1.12) 0.044 6 (0–48)
Limiting to DAY et al. [18]
SNPs
87536 33 −0.17 (−0.27–−0.08) 4.39×10−4 44 (20–83) 1.05 (0.99–1.12) 0.077 6 (0–52)
Significant results are shown in bold. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; LLN: lower limit of normal; SNP: single
nucleotide polymorphism; I2: between-instrument heterogeneity indicator; BMI: body mass index; NA: not applicable. #: all pleiotropic SNPs
associated with height, BMI and age at menarche excluded from the analysis and SNPs associated with the traits were selected based on the
results from the PhenoScanner with p<7.94×10−4 (0.05/63); ¶: women with complete data on all variables included in the observational
analyses.
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FIGURE 3 Mendelian randomisation estimates of the effect of age at menopause on a) forced expiratory volume in 1s (FEV1)/forced vital capacity
(FVC) and b) airflow obstruction as measured by FEV1/FVC<lower limit of normal (LLN) in subgroup analyses by smoking status, menopause
hormone therapy (MHT) use and current body mass index (BMI). Data are presented with 95% CI. #: p<0.10; *: p<0.05; **: p<0.01; ***: p<0.001.
https://doi.org/10.1183/13993003.02421-2018 7
LUNG STRUCTURE AND FUNCTION | D.A. VAN DER PLAAT ET AL.
CI 1.00–1.19) that did not reach statistical significance. Late menopause was not associated with any of the
five lung function outcomes.
Discussion
Contrary to observational findings, our MR study suggests that early menopause has a protective effect on
airflow obstruction, with no clear evidence of an effect on FVC or spirometric restriction [5, 31–35]. We
found a 15% decrease in the risk of airflow obstruction for women with menopause before the age of
45 years compared to women with a normal age at menopause, and this protective effect was less strong in
women who had used MHT as well as in overweight women. Although there was some evidence of
pleiotropy, overall our findings were consistent when using MR methods robust to pleiotropy.
MR studies can be considered similar to randomised controlled trials (RCTs) in that exposure to a specific
genetic variant is assigned randomly at conception. MR estimates are therefore not affected by classical
confounding factors. However, MR studies can provide evidence of a causal effect only if the three key
assumptions underlying MR hold (figure 1) [36, 37]. The first assumption (relevance assumption) is that
the SNPs used as instruments are associated with menopause, and we strengthened this by removing weak
instruments (F-statistic <10). The second assumption (independence assumption) is that the association
between the SNP and the outcome is not confounded. The third, and most important, assumption
(exclusion restriction) is the absence of pleiotropy, i.e. the SNP is not associated with other traits that
independently affect the outcome. Related to assumption 2, the main confounder for genetic associations
is population stratification, and we addressed this by adjusting for ancestry principal components. The
impact of violations of assumptions 2 and 3 can be assessed by excluding SNPs known to be associated
with traits that could affect lung function. We a priori considered height, BMI and age at menarche as
potential sources of confounding and/or pleiotropy because these traits are associated with lung function,
and 25%, 8% and 6% respectively of the 63 included SNPs have been previously associated with these
traits. Removing these SNPs resulted in similar results to those of the main analyses, suggesting no major
impact on the MR results through genetic associations of these traits. The presence of pleiotropy can also
be investigated by looking at the variation between MR estimates from the individual SNPs. We would
expect the individual MR estimates to vary only by chance if all included SNPs were valid instruments
(i.e. no pleiotropy) [22]. There was a suggestion of pleiotropy in our main analyses on FEV1/FVC, FVC
and airflow obstruction (I2=16–48), but not for spirometric restriction (I2=0). However, when we excluded
possible pleiotropic SNPs, there was still residual heterogeneity (I2=2–57), which could be due to other
(unknown) independent pathways. It is important to note that I2 is not independent of sample size or
number of instruments, and with large sample sizes high I2 values might be observed in the absence of
pleiotropy [22]. The consistency between the findings of the different MR methods provides reassurance
and indicates the robustness of our findings related to airflow obstruction.
Our findings when using age at menopause as a continuous variable were consistent with those for early and
late menopause. Of note, this MR analysis had 90% power to detect a minimum difference in FVC of 6.4 mL
per year increase in age at menopause, and hence we cannot exclude a smaller effect of age at menopause on
FVC [38]. Our main analyses suggested the possibility of a small detrimental effect of early menopause on
FVC (−5 mL, p=0.08). When we excluded possible pleiotropic SNPs, this association became significant
(p=0.03) and its direction was the same as in the observational analysis, although of much smaller
magnitude (−6.7 mL versus −36 mL). We thus cannot confirm the detrimental effect of early menopause
on FVC found in observational analyses, but if there is a true causal effect this is likely to be small.
Most observational studies report lower FEV1 and FVC in post-menopausal women compared to
pre-menopausal, but no change in FEV1/FVC or airflow obstruction [5, 31–35]. AMARAL et al. [5] studied
the effect of age at menopause (categorised into five groups) on lung function in the UKB and found that
an earlier age at menopause associated with lower FVC and FEV1, and with a higher risk of spirometric
restriction. In line with this study, but focusing on early and late menopause and adjusting for additional
potential confounders, our observational analysis in UKB showed strong associations of early menopause
with lower FVC and a 13% higher risk of spirometric restriction. Based on the same UKB study
population but using MR, we found strong associations of early menopause with higher FEV1/FVC and a
15% lower risk of airflow obstruction. We could not confirm a strong effect on FVC nor spirometric
restriction using MR. We may have found a protective effect of early menopause on airflow obstruction in
MR that we did not find in observational studies because of confounding of the observational findings by
factors that increase the risk of early menopause and decrease lung function, which could include early life
factors, diet and occupational exposures. Confounding might also explain why early menopause is
associated with a stronger reduction in FVC in observational analyses compared to MR. Future studies
that can account for more potential confounders could help explain the inconsistency between
observational and MR findings.
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Menopause marks the end of the reproductive period, which is defined as the time between menarche and
menopause. Age at menopause was highly correlated with the length of the reproductive period in our
data (correlation coefficient of 0.93). Early menopause might thus reflect the effect of a shorter lifetime
“exposure” to female sex hormones. We would expect less of an effect of early menopause on airflow
obstruction in women who still have high levels of female sex hormones after menopause, including
women taking hormonal therapies and obese women with higher endogenous levels. We therefore
performed subgroup analyses by MHT use and by BMI, and found that the effect of early menopause on
airflow obstruction was not so apparent in these groups, supporting this hypothesis. The role of sex
hormones in the lung is complex and there are biological reasons to support either a beneficial or a
detrimental effect depending on the type of hormone, concentration, duration of exposure, cell type and
their interactions [2, 39]. Beneficial effects of hormone therapy on lung function after 3–6 months MHT
use have been reported by small RCTs, while a crossover RCT reported no improvement in lung function
after MHT use [40–43]. Previous research in mice has shown that oestrogens may potentiate the oxidative
stress after smoking exposure, and thereby contribute to airway remodelling [29]. We therefore performed
subgroup analyses by smoking status, but found no evidence of a difference between smokers and
non-smokers.
Although technically the reproductive period is also defined by menarche, age at menarche varies very
little compared to age at menopause and therefore influences lifetime exposure to sex hormones to a much
lesser extent than age at menopause. Interestingly, an earlier age at menarche has previously been
associated with a reduced FVC in adult women in a previous MR study, while no association was found
for FEV1/FVC [38]. The proposed mechanism for the effect of early menarche relates to premature
completion of lung development and a lower maximal attained lung function, which has been confirmed
by an observational longitudinal study [44]. Therefore, the effect of age at menarche on lung function
might not be through sex hormones, unlike what we hypothesised for age at menopause.
A limitation of our study is the use of self-reported information on age at menopause. However, the
misclassification is likely to be random and the measurement error would reduce power rather than
causing bias. UKB did not perform post-bronchodilator pulmonary function measurements, so we cannot
distinguish between reversible and fixed airflow obstruction. When we excluded patients with self-reported
asthma from the MR analyses, we found almost identical results compared to the main analysis. Strengths
of our study are the large sample size, which is needed for MR, and the 6% variance in age at menopause
explained by the SNPs used in our MR, which is relatively high.
In conclusion, this MR study suggests that the earlier a woman’s menopause, the less likely she is to have
airflow obstruction. Future research is needed to further assess the effect of female sex hormones and the
length of the reproductive period on lung function. In addition, our MR study could not confirm a strong
effect of early menopause on FVC and spirometric restriction as found in observational studies, and
further work might explain this inconsistency.
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